(CURE) Direxion Daily Healthcare - Overview
Etf: Pharmaceuticals, Biotechnology, Equipment, Providers, Technology
Dividends
| Dividend Yield | 1.38% |
| Yield on Cost 5y | 1.61% |
| Yield CAGR 5y | 148.13% |
| Payout Consistency | 49.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 42.9% |
| Relative Tail Risk | 0.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.29 |
| Alpha | -18.44 |
| Character TTM | |
|---|---|
| Beta | 1.496 |
| Beta Downside | 1.484 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.93% |
| CAGR/Max DD | 0.09 |
Description: CURE Direxion Daily Healthcare January 17, 2026
The Direxion Daily Healthcare Bull 3X Shares (CURE) seeks to deliver three times the daily performance of a benchmark index composed of U.S. healthcare companies-including pharmaceuticals, biotech, medical devices, health-care services, and health-tech-by investing at least 80 % of its net assets in leveraged financial instruments. Because the fund is classified as non-diversified, a single issuer can represent more than 20 % of its holdings, amplifying both upside potential and downside risk.
Key data points to watch: the fund’s expense ratio is 0.95 % (annualized), and its average daily trading volume in Q1 2024 exceeded 1.2 million shares, indicating strong liquidity for a leveraged ETF. Sector-wide drivers include a projected 4.5 % YoY growth in U.S. health-care spending and a 12 % YoY increase in biotech capital expenditures, both of which can boost the underlying index’s momentum. However, the 3× leverage magnifies volatility; a 2 % move in the index can translate to a ~6 % swing in CURE’s price, and daily rebalancing can cause performance drift over longer horizons.
For a deeper quantitative breakdown of CURE’s risk-return profile, you might explore the ValueRay platform.
What is the price of CURE shares?
Over the past week, the price has changed by +5.43%, over one month by -2.44%, over three months by +21.90% and over the past year by +5.55%.
Is CURE a buy, sell or hold?
What are the forecasts/targets for the CURE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 118.7 | 2.9% |
CURE Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 185.9m USD (185.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 185.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 185.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 11.43% (E(185.9m)/V(185.9m) * Re(11.43%) + (debt-free company))
Discount Rate = 11.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)